|
FY2026
12 months to Jul 31, 2026
|
FY2025
12 months to Jul 31, 2025
|
FY2024
12 months to Jul 31, 2024
|
FY2023
12 months to Jul 31, 2023
|
FY2022
12 months to Jul 31, 2022
|
|
|---|---|---|---|---|---|
| Cash flow from operating activities: | |||||
| Loss | |||||
| Net loss for the year | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Amortization | |||||
| Financial income, net | |||||
| Depreciation | |||||
| Share-based compensation | |||||
| Share of loss on equity investment | |||||
| Change in fair value of warrants | |||||
| Unrealized gain on BC Therapeutics investment | |||||
| Changes in working capital: | |||||
| Decrease (increase) in amounts receivable | |||||
| Decrease (increase) in prepaid expenses | |||||
| (Decrease) increase in accounts payable | |||||
| Increase (decrease) in accrued expenses and other payables | |||||
| Net cash used in operating activities | |||||
| Cash flow from investing activities: | |||||
| Purchase of property and equipment | |||||
| Purchase of short-term investments, net | |||||
| Proceeds from short-term investments | |||||
| Equity investment in BC Therapeutics | |||||
| Net cash used in investing activities | |||||
| Cash flow from financing activities: | |||||
| Proceeds from exercise of warrants | |||||
| Proceeds from issuance of shares, net of issuance costs ($2,894,567 and $6,277,240, respectively) | |||||
| Share issuance costs | |||||
| Net cash provided by financing activities | |||||
| Increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of year | |||||
| Cash and cash equivalents at end of year | |||||
Loading...